Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Maria Romina Luca


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


M.R. Luca1, M. Angel2, F. Esteso3, J. Mariani4, F. Sanchez Loria2, M. Chacon2, J.M. O´Connor2

Author affiliations

  • 1 Oncology, Alexander Fleming Institute, C1426ANZ - Buenos Aires/AR
  • 2 Oncology, Alexander Fleming Institute, 1426 - CABA/AR
  • 3 Oncology, Alexander Fleming Institute, 1426 - caba/AR
  • 4 Oncology, alexander Fleming Institute, 1426 - caba/AR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1619


In patients with advanced CRC, KRAS mutations predicts response to treatment with EGFR inhibitor. The Liver metastases selection criteria include anatomic and biological variables. Recent evidence support the prognostic value of KRAS (molecular criteria) in pts with resectable hepatic metastases irrespective of systemic treatment. PURPOSE: To investigate the prognostic value of KRAS in patients undergoing liver resection for colorectal liver metastases (CRLM). Tumour sidedness and tumour burden was also evaluated.


Pubmed, Emabase and Cochrane Library databases were searched systematically. Data from published full-text articles reporting KRAS-stratified survival outcomes, recurrence free survival (RFS) and/or overall survival (OS) after resection of CRLM cancer. METHEPAR results, a local multi-institutional CRLM database, was also included. Hazard ratios (HR) and 95% CI from analyses were pooled in meta-analysis, and a random-effects model was used to calculate overall results.


The search returned 69 articles, of which 20, including METHEPAR, met the inclusion criteria. A total of 3819 patients were included. The mutation rate was 33.5% (IQR: 26.3-38.5). Pooled analysis showed that KRAS mutations predicted a significantly worse both RFS (HR: 1.55; 95% CI: 1.38-1.75) and OS (HR: 1.85; 95% CI: 1.57-2.19) in patients who underwent surgical resection of CRLM. In a subgroup analysis regarding sideness, studies involving more proportion of ptes with right sided tumours, had similar OS compare to those with proportion (HR:1.74; 95% CI 1.40; 2.16) p = 0.19. Liver-only mets had a similar OS compare to those with more disseminated diseasés burden (HR:1.76;95% CI1.46; 2.12).


This meta-analysis confirm, as in previous one that KRAS mutations is a poor prognostic biomarker, associated with worse survival outcomes, in patients undergoing hepatic resection of CRLM, regardless of tumor sidedness and disease burden. KRAS mutation should be considered in the evaluation of pts. having liver metastasis for surgical resection.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Alexander Fleming Institute.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.